Neurological Institute Outcomes
Brain Tumors
Supratentorial Craniotomy
Survival: Supratentorial Craniotomy
2017 – 2021
The 30- and 180-day survival rates were 99% and 96%, respectively, for 2021.
Supratentorial Craniotomy: Inpatient Mortality
2017 – 2021
ᵃThe 3M™ All Patient Refined Diagnosis Related Groups (APR-DRG) Classification System is used for adjusting data for severity of illness and risk of mortality.
Inpatient mortality remained lower than expected, continuing the trend during the past 5 years. N = number of supratentorial craniotomies performed for brain tumor per year. For 2021 the inpatient mortality was 0.42% while the expected mortality was 10.44%.
Supratentorial Craniotomy: Length of Stay
2017 – 2021
LOS = length of stay
ᵃThe 3M™ All Patient Refined Diagnosis Related Groups (APR-DRG) Classification System is used for adjusting data for severity of illness and risk of mortality.
Average length of stay remained below target, continuing the trend during the past 5 years.
Supratentorial Craniotomy for Glioma
2017 – 2021
The 30- and 180-day survival rates for supratentorial craniotomy for glioma were 99% and 93%, respectively, for 2021.
Supratentorial Craniotomy for Meningioma
2017 – 2021
Both the 30- and 180-day survival rates for supratentorial craniotomy for meningioma were 99% for 2021.
Supratentorial Craniotomy for Metastasis
2017 – 2021
The 30- and 180-day survival rates for supratentorial craniotomy for brain metastasis were 100% and 88%, respectively, for 2021.